Resazurin Microtiter Assay Plate Testing of Mycobacterium tuberculosis Susceptibilities to Second-Line Drugs: Rapid, Simple, and Inexpensive Method

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 11, 2003, Pages 3616-3619

  Martin, Anandi ^a   Camacho, Mirtha ^b   Portaels, Françoise ^a   Palomino, Juan Carlos ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Instituto Nacional de Laboratorios de Salud Bolivia   (Bolivia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; ETHIONAMIDE; KANAMYCIN; OFLOXACIN; RESAZURIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIUM ISOLATE; COLORIMETRY; CONTROLLED STUDY; INTERMETHOD COMPARISON; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROPORTION METHOD;

ANTITUBERCULAR AGENTS; COLORIMETRY; DRUG RESISTANCE, BACTERIAL; INDICATORS AND REAGENTS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZINES; REPRODUCIBILITY OF RESULTS; XANTHENES;

EID: 0242290941     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.11.3616-3619.2003     Document Type: Article

References (50)

1. Abate, G., R. N. Mshana, and H. Miorner. 1998. Evaluation of a colorimetric assay based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2:1011-1016.
2. Barnes, P. F., D. L. Lakey, and W. J. Burman. 2002. Tuberculosis in patient with HIV infection. Infect. Dis. Clin. N. Am. 16:107-126.
3. Bastian, I., and R. Colebunders. 1999. Treatment and prevention of multidrug-resistant tuberculosis. Drugs 58:633-661.
4. Bastian, I., L. Rigouts, J. C. Palomino, and F. Portaels. 2001. Kanamycin susceptibility testing of Mycobacterium tuberculosis using Mycobacterium Growth Indicator Tube and a colorimetric method. Antimicrob. Agents Chemother. 45:1934-1936.
5. Bloch, A. B., G. M. Cauthen, I. M. Onorato, K. G. Dansbury, G. D. Kelly, C. R. Driver, and D. E. Snider, Jr. 1994. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 271:665-671.
6. Brudney, K., and J. Dobkin. 1991. Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am. Rev. Respir. Dis. 144:745-749.
7. Canetti, G., F. Froman, J. Grosset, P. Hauduroy, M. Langerova, H. T. Mahler, G. Meissner, D. A. Mitchison, and L. Sula. 1963. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull. W. H. O. 29:565-578.
8. Canetti, G., W. Fox, A. Khomenko, H. T. Mahler, N. K. Menon, D. A. Mitchison, N. Rist, and N. A. Smelev. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. W. H. O. 41:21-43.
9. Caviedes, L., J. Delgado, and R. H. Gilman. 2002. Tetrazolium microplate assay as a rapid and inexpensive colorimetric method for determination of antibiotic susceptibility of Mycobacterium tuberculosis. J. Clin. Microbiol. 40:1873-1874.
10. Chaves, F., F. Dronda, M. D. Cave, M. Alonso-Sanz, A. Gonzalez-Lopez, K. D. Eisenach, A. Ortega, L. Lopez-Cubero, I. Fernandez-Martin, S. Catalan, and J. H. Bates. 1997. A longitudinal study of transmission of tuberculosis in a large prison population. Am. J. Respir. Crit. Care Med. 155:719-725.
11. Chen, C. H., J. F. Shih, P. J. Lindholm-Levy, and L. B. Heifets. 1989. Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan. Am. Rev. Respir. Dis. 140:987-989.
12. Cohn, D. L., F. Bustreo, M. C. Raviglione, et al. 1997. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. Clin. Infect. Dis. 24(Suppl. 1):S121-S130.
13. Collins, L. A., and S. G. Franzblau. 1997. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 41:1004-1009.
14. Espinal, M. A., A. Laszlo, L. Simonsen, F. Boulahbal, S. J. Kim, A. Reniero, S. Hoffner, H. L. Rieder, N. Binkin, C. Dye, R. Williams, M. C. Raviglione, et al. 2001. Global trends in resistance to antituberculosis drugs. N. Engl. J. Med. 344:1294-1303.
15. Espinal, M. A., C. Dye, M. Raviglione, and A. Kochi. 1999. Rational 'DOTS plus' for the control of MDR-TB. Int. J. Tuberc. Lung Dis. 3:561-563.
16. Espinal, M. A., K. Laserson, M. Camacho, Z. Fusheng, S. J. Kim, R. E. Tlali, I. Smith, P. Suarez, M. L. Antunes, A. G. George, N. Martin-Casabona, P. Simelane, K. Weyer, N. Binkin, and M. C. Raviglione. 2001. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int. J. Tuberc. Lung Dis. 5:887-893.
17. Espinal, M. A., S. J. Kim, P. G. Suarez, K. M. Kam, A. G. Khomenko, G. B. Migliori, J. Baez, A. Kochi, C. Dye, and M. C. Raviglione. 2000. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283:2537-2545.
18. Farmer, P., and J. Y. Kim. 1998. Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus." BMJ 317:671-674.
19. Foongladda, S., D. Roengsanthia, W. Arjrattanakool, C. Chuchottaworn, A. Chaiprasert, and S. G. Franzblau. 2002. Rapid and simple MTT method for rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 6:1118-1122.
20. Franzblau, S. G., R. S. Witzig, J. C. McLaughlin, P. Torres, G. Madico, A. Hernandez, M. T. Degnan, M. B. Cook, V. K. Quenzer, R. M. Ferguson, and R. H. Gilman. 1998. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 36:362-366.
21. Frieden, T. R., T. Sterling, A. Pablos-Mendez, J. O. Kilburn, G. M. Cauthen, and S. W. Dooley. 1993. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 328:521-526.
22. Gupta, R., M. C. Raviglione, and M. A. Espinal. 2001. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? Int. J. Tuberc. Lung Dis. 5:1078-1079.
23. Harries, A. D., D. Maher, B. Mvula, and D. Nyangulu. 1995. An audit of HIV testing and HIV serostatus in tuberculosis patients, Blantyre, Malawi. Tuber. Lung Dis. 76:413-417.
24. Heifets, L. B., and P. J. Lindholm-Levy. 1987. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle 68:267-276.
25. Heifets, L. B., P. J. Lindholm-Levy, and M. Flory. 1991. Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 143:268-270.
26. Heifets, L., and P. Lindholm-Levy. 1989. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis. Antimicrob. Agents Chemother. 33: 1298-1301.
27. Horobin, R. W. 2001. The problem of proprietary dyes, with special reference to Alamar blue, a proprietary dye revealed. Biotech. Histochem. 76:163-164.
28. Kazionny, B., C. D. Wells, H. Lue, N. Gusseynova, and V. Molotilov. 2002. Implications of the growing HIV-1 epidemic for tuberculosis control in Russia. Lancet 358:1513-1514.
29. Loddenkemper, R., D. Sagebiel, and A. Brendel. 2002. Strategies against multidrug-resistant tuberculosis. Eur. Respir. J. Suppl. 36:66s-77s.
30. Mitnick, C., J. Bayona, E. Palacios, S. Shin, J. Furin, F. Alcantara, E. Sanchez, M. Sarria, M. Becerra, M. C. Fawzi, S. Kapiga, D. Neuberg, J. H. Maguire, J. Y. Kim, and P. Farmer. 2003. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. 348:119-128.
31. Mshana, R. N., G. Tadesse, G. Abate, and H. Miörner. 1998. Use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 36:1214-1219.
32. Nachega, J. B., and R. E. Chaisson. 2003. Tuberculosis drug resistance: a global threat. Clin. Infect. Dis. 36:S24-S30.
33. NCCLS. 2000. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic actinomycetes; tentative standard, 2nd ed. Document M24-T2. NCCLS, Wayne, Pa.
34. O'Brien, J., I. Wilson, T. Orton, and F. Pognan. 2000. Investigation of the Alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 267:5421-5426.
35. Pablos-Mendez, A., D. K. Gowda, and T. R. Frieden. 2002. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull. W. H. O., 80:489-495.
36. Pablos-Mendez, A., M. C. Raviglione, A. Laszlo, N. Binkin, H. L. Rieder, F. Bustreo, D. L. Cohn, C. S. Lambregts-van Weezenbeek, S. J. Kim, P. Chaulet, P. Nunn, et al. 1998. Global surveillance for antituberculosis-drug resistance, 1994-1997. N. Engl. J. Med. 338:1641-1649.
37. Palomino, J.-C., A. Martin, M. Camacho, H. Guerra, J. Swings, and F. Portaels. 2002. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:2720-2722.
38. Palomino, J. C., and F. Portaels. 1999. Simple procedure for drug susceptibility testing of Mycobacterium tuberculosis using a commercial colorimetic assay. Eur. J. Clin. Microbiol. Infect. Dis. 18:380-383.
39. Pfyffer, G. E., A. Strassle, T. Van Gorkum, F. Portaels, L. Rigouts, C. Mathieu, F. Mirzoyev, H. Traore, and J. D. Van Embden. 2001. Multidrug-resistant tuberculosis in prison inmates, Azerbaijan. Emerg. Infect. Dis. 7:855-861.
40. Pfyffer, G. E., D. A. Bonato, A. Ebrahimzadeh, W. Gross, J. Hotaling, J. Kornblum, A. Laszlo, G. Roberts, M. Salfinger, F. Wittwer, and S. Siddiqi. 1999. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J. Clin. Microbiol. 37:3179-3186.
41. Portaels, F., L. Rigouts, and I. Bastian. 1999. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Int. J. Tuberc. Lung Dis. 3:582-588.
42. Pracharktam, R., K. Angkananukool, and A. Vibhagool. 2001. In vitro susceptibility testing of levofloxacin and ofloxacin by microtiter plate Alamar blue against multidrug and non multidrug resistant Mycobacterium tuberculosis in Thailand. J. Med. Assoc. Thail. 84:1241-1245.
43. Rasmussen, E. V. 1999. Use of fluorescent redox indicators to evaluate cell proliferation and viability. In Vitro Mol. Toxicol. 12:47-58.
44. Rastogi, N., V. Labrousse, and K. S. Goh. 1996. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr. Microbiol. 33:167-175.
45. Roberts, G. D., N. L. Goodman, L. Heifets, H. W. Larsh, T. H. Lindner, J. K. McClatchy, M. R. McGinnis, S. H. Siddiqi, and P. Wright. 1983. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J. Clin. Microbiol. 18:689-696.
46. Siddiqi, S. H., J. P. Libonati, and G. Middlebrook. 1981. Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 13:908-912.
47. World Health Organization. 2001. Global tuberculosis control. WHO. report WHO/CDS/B2001.287. World Health Organization, Geneva, Switzerland.
48. World Health Organization. 2000. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug resistant tuberculosis (MDRTB). WHO report WHO/ODS/TB/2000.279. World Health Organization, Geneva, Switzerland.
49. Yajko, D. M., J. J. Madej, M. V. Lancaster, C. A. Sanders, V. L. Cawthon, B. Gee, A. Babst, and W. K. Hadley. 1995. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J. Clin. Microbiol. 33:2324-2327.
50. Zeig, M. H., and G. Campbell. 1993. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39:561-577.